Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Merck KGaA. (7/24/14). "Press Release: Merck Serono Announces Collaboration with San Raffaele University and Research Hospital for Research in Neurodegenerative Diseases". Darmstadt.

Organisations Organisation Merck Serono (division of Merck KGaA)
  Group Merck (DE) (Group)
  Organisation 2 Università Vita-Salute San Raffaele (San Raffaele University & Research Hospital)
  Group San Raffaele of Monte Tabor Foundation
Products Product drug development
  Product 2 neurology
Index term Index term Merck (DE)–San Raffaele: drug development, 201407– collab extension pre- + clinical research drugs for neurodegenerative diseases Merck Serono
Person Person Parmar, Harsukh (Merck (DE) 201404 Head Translational Innovation Platform at Merck Serono)
     


> Agreement for research in neurodegenerative diseases continues collaboration to develop pre-clinical and clinical research projects with a translational approach

> Research to focus on developing innovative therapies against serious and disabling neurological diseases affecting young adults in particular


Merck Serono, the biopharmaceutical division of Merck, and the Institute of Experimental Neurology (INSPE), part of San Raffaele University and Research Hospital in Milan, Italy, announced today the continuation of a strategic alliance to develop pre-clinical and clinical research projects in the field of neurodegenerative diseases.

The research will focus on developing innovative therapies against serious and disabling neurological diseases affecting young adults in particular, such as multiple sclerosis. Established in 2004, the renewal of the partnership extends the agreement between the parties for two additional years.

"Merck Serono is pleased to continue the collaborative alliance with the San Raffaele Scientific Institute," said Harsukh Parmar, Senior Vice President, Global Head of Research & Early Development, Immunology & Neurologyat Merck Serono. "Our translational approach to these disease states and combined commitment to expediting the discovery of new therapies aims to improve health outcomes for patients living with unmet medical needs."

"The co-operation between pharmaceutical companies and both private and public research institutes is a fundamental instrument to finance the research, a delicate and critical issue," said Professor Giancarlo Comi, director of INSPE and of the department of neurology at San Raffaele Hospital. "In compliance with the respective prerogatives and role of research institutions and companies in the pharmaceutical market, these forms of collaboration allow research institutes to actively participate as real drivers at the development of new therapies and at the definition of biomarkers, as essential tools for the drugs optimization."

San Raffaele University and Research Hospital will provide its know-how and its laboratories to develop new therapies and to evaluate the effectiveness of the molecules developed by Merck Serono.


About Merck Serono

Merck Serono is the biopharmaceutical division of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit www.merckserono.com.


All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.


Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world's oldest pharmaceutical and chemical company - since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

   
Record changed: 2017-04-02

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Merck (DE) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top